Linked Life Data

11993408

Source:http://linkedlifedata.com/resource/pubmed/id/11993408

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2002-5-7
pubmed:abstractText
This study was conducted in 19 patients with mild or moderate essential hypertension randomised open trial to evaluate the influence of potassium losartan dosed 50 mg per day on blood pressure, metabolic processes and left ventricular heart function. The following intervals of examination were accepted-at entry (before therapy with losartan) and then after 10 days; after 30 days and after 60 days of treatment. Mean values of arterial blood pressure and heart rate measured by conventional technics and obtained from 24-hour ambulatory monitoring data, biochemical results (serum levels of glucose, uric acid, creatinine, sodium, potassium, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, bilirubin and serum activity of aminotransferases) and selected indices of left ventricular heart function were evaluated as intragroup differences using Student's paired t test. Afterwards the body mass index was compared. Statistically significant decrease of systolic arterial pressure after 60 days of therapy was revealed and it concerned both diurnal period and sleep time and during whole 24 hours. During treatment with losartan mean creatinine serum level was increased and the serum level of bilirubin was decreased in serum after 10 days of therapy. No significant changes were noted in any other laboratory parameters. After 30 and 60 days of treatment with potassium losartan thickness of interventricular septum end-diastole (IVS-D) diminished and E/A ratio (transmitral flow during early ventricular diastole to peak velocity of late filling) augmented statistically significantly after 30 days of treatment. In addition body mass index was increased after 10 days of therapy with losartan when compared with this index at the entry. This study confirmed profitable antihypertensive losartan effect as significant decrease of systolic blood pressure and demonstrated improve diastolic function of left ventricle during therapy in patients with mild or moderate essential hypertension.
pubmed:language
pol
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0032-3772
pubmed:author
pubmed:issnType
Print
pubmed:volume
106
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
891-9
pubmed:dateRevised
2010-4-1
pubmed:meshHeading
pubmed-meshheading:11993408-Adult, pubmed-meshheading:11993408-Aged, pubmed-meshheading:11993408-Anti-Arrhythmia Agents, pubmed-meshheading:11993408-Antihypertensive Agents, pubmed-meshheading:11993408-Bilirubin, pubmed-meshheading:11993408-Blood Glucose, pubmed-meshheading:11993408-Blood Pressure, pubmed-meshheading:11993408-Blood Pressure Monitoring, Ambulatory, pubmed-meshheading:11993408-Cholesterol, pubmed-meshheading:11993408-Female, pubmed-meshheading:11993408-Humans, pubmed-meshheading:11993408-Hypertension, pubmed-meshheading:11993408-Losartan, pubmed-meshheading:11993408-Male, pubmed-meshheading:11993408-Middle Aged, pubmed-meshheading:11993408-Potassium, pubmed-meshheading:11993408-Sodium, pubmed-meshheading:11993408-Time Factors, pubmed-meshheading:11993408-Treatment Outcome, pubmed-meshheading:11993408-Triglycerides, pubmed-meshheading:11993408-Uric Acid, pubmed-meshheading:11993408-Ventricular Function, Left
pubmed:year
2001
pubmed:articleTitle
[Estimation of blood pressure, selected biochemical parameters and indices of left ventricular heart function in patients with mild or moderate essential hypertension treated with potassium losartan].
pubmed:affiliation
Klinika Chorób Wewnetrznych i Farmakologii Klinicznej Sl. AM w Katowicach.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract, Randomized Controlled Trial